7月17日，寒武纪发布公告，宣布调整2025年度向特定对象发行A股股票方案。根据最新方案，公司拟 发行股票数量不超过2091.75万股，募集资金总额不超过39.85亿元。募集资金扣除发行费用后，将主要 用于面向大模型的芯片平台项目、面向大模型的软件平台项目及补充流动资金。 近年来，寒武纪的智能芯片产品在运营商、金融、互联网等多个垂直行业加速落地，并与大模型领域企 业展开深度适配与合作，获得行业客户的高度认可。公司掌握的智能处理器指令集、微架构、编程语 言、数学库等核心技术，具备高壁垒、强生态价值，对人工智能及集成电路产业发展具有重要意义。 随着ChatGPT等大模型的爆发，全球AI算力需求呈指数级增长，高端智能芯片市场迎来黄金发展期。寒 武纪此次募资加码大模型相关技术，不仅顺应行业趋势，也有望进一步提升国产AI芯片的自主创新能 力，在未来的全球AI算力竞争中占据更有利位置。 市场分析人士指出，寒武纪作为国内少数具备全栈AI芯片技术能力的企业，此次定增若顺利实施，将 显著增强其在大模型时代的核心竞争力，并为国产AI芯片生态的完善注入强劲动力。 寒武纪表示，当前大模型的快速发展正推动人类社会加速迈向强人工智能时代 ...

关于中科寒武纪科技股份有限公司 审核问询函的回复 保荐机构（主承销商） 广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座 二〇二五年七月 上海证券交易所： 贵所于 2025 年 6 月 16 日出具的上证科审（再融资）〔2025〕64 号《关于 中科寒武纪科技股份有限公司向特定对象发行股票申请文件的审核问询函》（以 下简称"问询函"）已收悉，中科寒武纪科技股份有限公司（以下简称"寒武纪"、 "发行人"、"公司"）、中信证券股份有限公司（以下简称"保荐机构"、"中 信证券"）对问询函中的相关问题逐项进行了研究和落实，现对问询函问题回复 如下，请予审核。 如无特别说明，本问询函回复报告中的简称或名词的释义与《中科寒武纪科 技股份有限公司 2025 年度向特定对象发行 A 股股票募集说明书》中的相同。本 回复中所列数据可能因四舍五入原因而与数据直接相加之和存在尾数差异。 本回复报告的字体代表以下含义： 审核问询函所列问题 黑体 对问询函所列问题的回复 宋体 目 录 问题 1 关于本次募投项目 根据申报材料，公司拟向特定对象发行 A 股股票募集资金总额不超过 目和补充流动资金。 请发行人说明：（1）结合大模 ...

每日经济新闻 （责任编辑：张晓波 ） 【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容 的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱： news_center@staff.hexun.com 没有股票账户的投资者可关注国泰中证机器人ETF发起联接A（020289），国泰中证机器人ETF发 起联接C（020290）。 注：如提及个股仅供参考，不代表投资建议。指数/基金短期涨跌幅及历史表现仅供分析参考，不 预示未来表现。市场观点随市场环境变化而变动，不构成任何投资建议或承诺。文中提及指数仅供参 考，不构成任何投资建议，也不构成对基金业绩的预测和保证。如需购买相关基金产品，请选择与风险 等级相匹配的产品。基金有风险，投资需谨慎。 华龙证券指出，叉车行业6月销量数据亮眼，当月销售各类叉车137570台，同比增长23.1%，其中 国内销量83892台，同比增长27.3%，出口量53678台，同比增长17.2%。1-6月累计销量739334台，同比 增长11.7%，内销同比增长9.79%，出口同比增长15.2%。随着人工 ...

生物医药ETF跟踪的是CS生医指数，该指数由中证指数有限公司编制，从沪深市场中选取涉及生物科 技、医疗设备、医疗服务等领域的上市公司证券作为指数样本，以反映生物医药行业相关上市公司证券 的整体表现。该指数具有较强的行业代表性与成长性，能够较好地体现生物医药产业的发展趋势。 招商证券指出，2024年全国医保基金运行安全稳健，管理服务提质增效，医保基金总收入和总支出均保 持同比增长趋势，职工医保和城乡居民医保累计结余分别达4.49万亿和8183亿元，基金整体运行平稳。 参保人数稳定在95%以上，职工医保参保人数同比增长2.3%，收入增长3.5%，支出增长7.6%；居民医 保收入增长5.78%，支出增长1.9%。"三医"协同发展和治理成效显著，为生物医药行业提供了稳定的支 付环境。创新出海产业趋势已现，持续看好创新药与医药消费机会，重组胶原蛋白新材料等技术实现突 破，消费医疗领域布局加速。行业基本面稳健，政策环境支持创新和国际化发展。 没有股票账户的投资者可关注国泰中证生物医药ETF联接A（006756），国泰中证生物医药ETF联接C （006757）。 注：如提及个股仅供参考，不代表投资建议。指数/基金短期涨跌幅 ...

"宁波膜智信息科技有限公司"为势银（TrendBank）唯一工商注册实体及收款账户 势银研究： 势银产业研究服务 势银数据： 势银数据产品服务 势银咨询： 势银咨询顾问服务 重要会议： 2025势银（银川）长时储能产业大会（7月14日-15日，宁夏·银川） 点此报名 重要会议： 2025势银绿氢产业大会（8月27-28日，江苏·无锡） 点此报名 添加文末微信，加 燃料电池 群 风起氢涌， 氢能 干线物流的黄金时代已至 。 从黄河腹地到长江之滨，从西部峻岭到京沪动脉 ——氢能重卡正以"零碳钢驼"之姿，重塑中国万公里物流干线。 早在去年，随着示范城市群概念的不断弱化，两纵四横氢走廊战略迅速兴起。其所覆盖的片区和国 家高速骨干通道网络高度重合，网络中的关键节点串联了全国 19个城市群，形成了一张全国性的 氢能高速流通网络。这不仅标志着中国燃料电池示范推广步入一个新阶段，从"点→线→面"发展， 从单一的城市内的运营向城市间的长途运输发展，同时也代表着燃料电池产品成熟度达到了较高的 水平。 步入 2025年，中国氢能干线物流再度迎来爆发式开局，延续火热发展势头： 随着这张氢能干线物流网的日益壮大，以及基础设施的逐步完善 ...

注：如提及个股仅供参考，不代表投资建议。指数/基金短期涨跌幅及历史表现仅供分析参考，不预示 未来表现。市场观点随市场环境变化而变动，不构成任何投资建议或承诺。文中提及指数仅供参考，不 构成任何投资建议，也不构成对基金业绩的预测和保证。如需购买相关基金产品，请选择与风险等级相 匹配的产品。基金有风险，投资需谨慎。 东吴证券表示，在汽车制造领域，优必选的WalkerS系列人形机器人已进入蔚来、比亚迪、奥迪一汽等 多家车厂，参与质检、贴标等任务，并与无人物流车协同作业，实现了零件入库流程的无人化。在医药 领域，越疆与药师帮签署战略合作协议，共同探索智慧解决方案在医药研发、仓储、配送、零售、用药 服务等全链场景的应用。在基础设施巡检领域，云深处的"绝影"系列四足机器人已在新加坡国家电网的 电力隧道中投入使用，执行自主巡检任务，提高了巡检效率和安全性。此外，智元机器人推出的灵犀 X2人形机器人，具备多模态交互能力，已应用于展厅讲解、文娱表演等场景，展示了人形机器人在服 务行业的潜力。预计未来随机器人智能性逐步提高，有望持续拓展更多应用场景。 机器人产业ETF（159551）紧密跟踪中证机器人指数，该指数选取系统方案商、 ...

Group 1 - The humanoid robot sector saw an increase, with the Robot Industry ETF (159551) rising over 1% [1] - Tianfeng Securities reported that several companies in the supply chain have recently launched cycloidal products for humanoid robots, which are expected to address weight issues [1] - Keda Li-Ke Meng has developed cycloidal products using PEEK materials, achieving a weight reduction of 73% compared to steel [1] Group 2 - Fuda-Changban holds multiple patents for cycloidal reducers [1] - Japanese Nabtesco has gradually introduced closed structure RD series reducers and lightweight N series reducers based on RV structures [1] - Domestic company Zhihong Technology has launched high-precision, long-life, highly integrated, and lightweight transmission module products for humanoid robots [1] Group 3 - The Robot Industry ETF (159551) closely tracks the CSI Robot Index, which includes listed companies related to system solution providers, digital workshops, automation equipment manufacturers, and automation component manufacturers [1] - The index reflects the overall performance of robot-related securities, providing investors with a convenient tool for investing in the robot industry [1] - Investors without stock accounts can access investment opportunities in the robot industry through the connecting fund of the Robot Industry ETF (020290) [2]

Group 1 - The ChiNext Index (399006) has shown a positive performance with a rise of 1.16%, highlighting the strength of key stocks such as Dongfang Caifu, which increased by 4.6%, and Mindray Medical, which rose by 1.8% [1] - The ChiNext ETF (159915) has gained significant attention, with its latest scale exceeding 84 billion, making it the largest among similar ETFs, and it has seen a net subscription of 1.11 million shares [1] - The report from Everbright Securities indicates that the second half of the year may see sustained corporate profit recovery, driven by improved domestic demand, favorable policies, and the rise of emerging industries such as artificial intelligence and robotics [2][3] Group 2 - The ChiNext Index is characterized by a high proportion of high-tech enterprises, strong R&D investment, and significant growth potential, reflecting China's economic transformation and upgrade [3] - The ChiNext ETF (159915) maintains a low fee structure, with management and custody fees at 20 basis points per year, aligning with the brand's low-cost philosophy [4] - Related products include the ChiNext ETF and its various linked funds, indicating a range of investment options for investors [5]

Group 1 - The National Healthcare Security Administration and the National Health Commission released measures to support the high-quality development of innovative drugs, including 16 policies to enhance the R&D environment and promote innovative drugs into insurance directories [1] - Domestic pharmaceutical companies have made breakthroughs in internationalization, with Dize Pharmaceutical's Shuwotini receiving FDA approval, marking it as the first domestic innovative drug approved for treating EGFR exon 20 insertion NSCLC in the U.S. [1] - The biopharmaceutical industry outperformed the pharmaceutical index and the broader market, with some companies benefiting from the recovery of the upstream pharmaceutical supply chain, indicating a trend of valuation recovery [1] Group 2 - The vaccine industry is facing performance pressure, but improvements in channel inventory may lead to a recovery or continued growth in sales for key vaccine products such as PCV13, diploid rabies vaccine, and MCV4 [1] - Blood product companies are experiencing price pressure post-collection for albumin and some blood products, but the industry is expected to see steady growth in plasma collection volume in 2024, supporting future growth [1] - The expansion of plasma stations and trends in mergers and acquisitions are areas of interest for future developments in the blood products sector [1]

Core Viewpoint - The photovoltaic sector is experiencing a significant rebound, with the leading photovoltaic ETF (516290) surging over 4% in trading volume, indicating a potential bottom reversal in the market [1] Group 1: Market Performance - The photovoltaic leading ETF (516290) saw a price increase of 4.47%, reaching 0.444, with a trading volume of 3,842 million [1] - Major component stocks of the ETF, such as Daqo New Energy, Tongwei Co., and Sungrow Power Supply, reported substantial gains, with Daqo New Energy rising over 14% and Tongwei Co. hitting the daily limit [1] Group 2: Industry Insights - In May, the newly installed capacity for photovoltaic systems reached 93 GW, marking a year-on-year increase of 388%, with a historical high of nearly 100 GW in new installations driven by a rush to install [2] - The photovoltaic industry is addressing supply-side excess, with expectations for specific measures to be implemented, which could benefit segments like silicon materials and BC battery efficiency improvements [3] Group 3: Future Outlook - The photovoltaic sector is anticipated to undergo a fundamental recovery, with positive sentiment expected to shift as new technologies and government initiatives promote market clearing [4] - The photovoltaic leading ETF (516290) is highlighted as a low-fee option in the market, with management and custody fees significantly lower than the industry average [4]